alexa The Role Of Intravenous Phospholipds As A Membrane Therapeutic-A Complementary Treatment Approach Of CKD (Chronic Kidney Disease)
ISSN: 2161-0959

Journal of Nephrology & Therapeutics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

12TH ANNUAL CONFERENCE ON Nephrology & Urology
JULY 06-07, 2017 KUALA LUMPUR, MALAYSIA

Michael D Wagener
Stellar Bio molecular Research (SBR) and FCTI, Germany
Keynote: J Nephrol Ther
DOI: 10.4172/2161-0959-C1-041
Abstract
Phosphatidylcholine is a phospholipid that is one of the main components of lecithin. Lecithin is found in all cell membranes and plays a major role in maintaining the fluidity of the cell by affecting what enters and leaves the cell through the cell membrane. Given as infusion, PC might improve many conditions, among them kidney function and overall energy. Clinical studies have been performed in glomerulonephritis, where a reduction of edema could be observed. Also in renal insufficiency patients showed an increase in creatinine, urine volume and renal clearance when receiving PC intravenously. Overall patients suffering from fatigue from various causes (e.g. Chronic Kidney Disease) were benefiting from phosphatidylcholine infusions. Standard toxicological assessments indicate no significant acute or chronic toxicity from PC, as well as no mutagenicity and no teratogenicity.
Biography

Michael D Wagener has received a Medical Degree from the University of Berlin, Germany, in 1991. During his Post-graduate training, he was trained in General Internal Medicine, Pneumology and Allergology in Davos (Switzerland). He received board certification in General Internal Medicine, Allergology and Pharmaceutical Medicine and Neuraltherapy. In 1997, he joined Eli Lilly as a Clinical Research Physician, in 2005 Novartis Pharma in Basel and in 2009 he became Chief Medical Officer of AC Immune in Lausanne (Switzerland). Since 2000, he was a member of the Executive Board of the Swiss Association of Pharmaceutical Medicine (SGPM) and in 2002 to 2008 he was elected President of this Organization. Since 2010, he is the Owner of an “Antiaging and Complementary Medicine Center” in Basel.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords